MIT Libraries logoDSpace@MIT

MIT
View Item 
  • DSpace@MIT Home
  • MIT Open Access Articles
  • MIT Open Access Articles
  • View Item
  • DSpace@MIT Home
  • MIT Open Access Articles
  • MIT Open Access Articles
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Controlled drug delivery systems for oral cancer treatment--current status and future perspectives

Author(s)
Koutsopoulos, Sotirios
Thumbnail
Downloadpharmaceutics-11-00302-v2.pdf (2.115Mb)
Publisher with Creative Commons License

Publisher with Creative Commons License

Creative Commons Attribution

Terms of use
Creative Commons Attribution https://creativecommons.org/licenses/by/4.0/
Metadata
Show full item record
Abstract
Oral squamous cell carcinoma (OSCC), which encompasses the oral cavity-derived malignancies, is a devastating disease causing substantial morbidity and mortality in both men and women. It is the most common subtype of the head and neck squamous cell carcinoma (HNSCC), which is ranked the sixth most common malignancy worldwide. Despite promising advancements in the conventional therapeutic approaches currently available for patients with oral cancer, many drawbacks are still to be addressed; surgical resection leads to permanent disfigurement, altered sense of self and debilitating physiological consequences, while chemo- and radio-therapies result in significant toxicities, all affecting patient wellbeing and quality of life. Thus, the development of novel therapeutic approaches or modifications of current strategies is paramount to improve individual health outcomes and survival, while early tumour detection remains a priority and significant challenge. In recent years, drug delivery systems and chronotherapy have been developed as alternative methods aiming to enhance the benefits of the current anticancer therapies, while minimizing their undesirable toxic effects on the healthy non-cancerous cells. Targeted drug delivery systems have the potential to increase drug bioavailability and bio-distribution at the site of the primary tumour. This review confers current knowledge on the diverse drug delivery methods, potential carriers (e.g., polymeric, inorganic, and combinational nanoparticles; nanolipids; hydrogels; exosomes) and anticancer targeted approaches for oral squamous cell carcinoma treatment, with an emphasis on their clinical relevance in the era of precision medicine, circadian chronobiology and patient-centred health care. ©2019 Keywords: oral, head and neck squamous cell carcinoma; targeted therapies; drug delivery systems; nanoparticles; controlled drug delivery; circadian clock; chronotherapy; precision medicine
Date issued
2019-06-30
URI
https://hdl.handle.net/1721.1/125310
Department
Massachusetts Institute of Technology. Center for Biomedical Engineering
Journal
Pharmaceutics
Publisher
Multidisciplinary Digital Publishing Institute
Citation
Ketabat, Farinaz, et al., "Controlled drug delivery systems for oral cancer treatment--current status and future perspectives." Pharmaceutics 11, 7 (June 2019): no. 302 doi 10.3390/pharmaceutics11070302 ©2019 Author(s)
Version: Final published version
ISSN
1999-4923

Collections
  • MIT Open Access Articles

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

Login

Statistics

OA StatisticsStatistics by CountryStatistics by Department
MIT Libraries
PrivacyPermissionsAccessibilityContact us
MIT
Content created by the MIT Libraries, CC BY-NC unless otherwise noted. Notify us about copyright concerns.